Malika Idayat

Mrs. Malika Idayat

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
MIMalika Idayat
Malika Idayat
ELElena von der Lippe
Elena von der Lippe
NKNailya Kozhekenova
Nailya Kozhekenova
Oyunzul AmartsengelOyunzul Amartsengel
Oyunzul Amartsengel
AKAkhmetova Kamila
Akhmetova Kamila
NGNatalya Glushkova
Natalya Glushkova
Background: In 2023, tuberculosis (TB) caused 1.25 million deaths globally, remaining a leading infectious killer. Central Asia and Southern Caucasus face high TB burdens, particularly Mongolia. This review synthesizes TB prevalence data and diagnostic capabilities in these regions to support public health strategies. Methods: This systematic review aimed to synthesize current data on TB prevalence in Central Asia, Southern Caucasus, and Mongolia to support public health strategies and research priorities. A comprehensive search of PubMed and Google Scholar was conducted for English-language articles published up to 2023. Studies were assessed using a modified Newcastle–Ottawa Scale. Nine studies met the inclusion criteria, covering Kazakhstan, Kyrgyzstan, Uzbekistan, Tajikistan, Turkmenistan, Mongolia, Georgia, Armenia, and Azerbaijan. Results: TB incidence ranged from 67 per 100,000 in Kazakhstan to 190 per 100,000 in Kyrgyzstan, with the highest prevalence of 68.5% in Mongolia. TB affected men more frequently (65.3%), and the key risk factors included HIV (30.5%), comorbidities, and undernutrition. Diagnostic performance varied significantly (microscopy sensitivity, 45–65%; GeneXpert MTB/RIF, 89–96% sensitivity and 98% specificity for rifampicin resistance). Diagnostic turnaround times ranged from hours (molecular) to weeks (conventional). Only 58% of TB facilities had GeneXpert technology, with urban–rural disparities in diagnostic access. Drug-resistant TB imposed a significant economic burden, with treatment costs ranging from USD 106 to USD 3125. Conclusions: Strengthening surveillance, improving data collection, and conducting longitudinal studies are essential for designing effective TB control strategies in these regions. Significant diagnostic gaps persist across these regions, especially with regard to drug-resistant strains. Point-of-care molecular diagnostics, improved algorithms, and expanded laboratory training show promise. Future research should focus on rapid biomarker-based diagnostics, field-deployable technologies for settings with limited resources, and AI integration to enhance diagnostic accuracy and efficiency.

15 May 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
OAOyunzul Amartsengel
Oyunzul Amartsengel
MIMalika Idayat
Malika Idayat
ARAlexander Rommel
Alexander Rommel
NGNatalya Glushkova
Natalya Glushkova
KDKairat Davletov
Kairat Davletov
ELElena von der Lippe
Elena von der Lippe
Background: In Central Asia, respiratory diseases, particularly tuberculosis (TB), are widespread communicable diseases that significantly impact both individuals and health systems, posing a substantial burden. Research highlights the importance of assessing the impact of TB on global morbidity statistics, given its status as a prominent contributor to global morbidity rates and the cause of over a million deaths annually. Our study aims to assess the patterns and changes in the burden of TB in Mongolia and Kazakhstan.Methods: The design is retrospective cross-sectional study. This study used the Global Burden of Disease (GBD) framework, which introduced disability-adjusted life years (DALY) as a measure of disease burden, combining mortality (Years of Life Lost, YLL) and morbidity (Years Lived with Disability, YLD). The calculations were based on standard GBD formulas, incorporating life expectancy data, age at death, and disease-specific disability weights. We calculated Mongolia’s and Kazakhstan’s national TB registration data from 2017 to 2021. From 2017 to 2021, Kazakhstan and Mongolia experienced significant declines in the burden of TB, as indicated by reductions in years of life lost and years living with disability.Findings: From 2017 to 2021, Kazakhstan’s YLL decreased by 18.2% and YLD by 36%, reflecting improved TB control. Mongolia experienced a 24.9% decline in YLL and a 39.4% reduction in YLD, although premature mortality in older men remains a challenge. These findings highlight the need for targeted interventions and healthcare equity to sustain TB control efforts. YLD rates remained low and had minimal impact on total DALYs, underlining the positive trends in reducing TB mortality and disability in both countries. Kazakhstan and Mongolia have significantly reduced the burden of TB, evidenced by reductions in DALY, YLL, and YLD rates.Interpretation: The results suggest that while TB control efforts have yielded positive results in both countries, Mongolia faces challenges in reducing TB-related mortality and morbidity, highlighting the need for targeted interventions and improved access to TB services. These results are consistent with global trends showing a declining TB burden due to improved diagnostics and treatment strategies but highlighting structural disparities that hinder uniform progress. Moreover, WHO estimates for the Western Pacific Region (WPR) and South-East Asia Region (SEAR) reported a slower increase in tuberculosis mortality trends from 2017 to 2021. Future research should focus on addressing the factors contributing to Mongolia’s persistently high TB burden, including access to healthcare, treatment adherence, and the role of comorbidities. In addition, expanding the scope of analysis to other Central Asian countries will provide a broader understanding of TB control efforts across the region.

28 April 2025 in medRxiv
Verified
Preprint
Open access
PDF file
MIMalika Idayat
Malika Idayat
NKNailya Kozhekenova
Nailya Kozhekenova
OAOyunzul Amartsengel
Oyunzul Amartsengel
KAKamila Akhmetova
Kamila Akhmetova
ELElena Von Der Lippe
Elena Von Der Lippe
NGNatalya Glushkova
Natalya Glushkova
In 2023, tuberculosis (TB) caused an estimated 1.25 million deaths globally, including 161,000 among people with HIV. After being temporarily surpassed by COVID-19, TB has likely returned as the leading cause of death from a single infectious agent. Central Asia and the Southern Caucasus remain high-burden regions, with Mongolia showing the highest TB prevalence. This systematic review aimed to synthesize current data on TB prevalence in Central Asia, Southern Caucasus, and Mongolia to support public health strategies and research priorities. A comprehensive search of PubMed and Google Scholar was conducted for English-language articles published up to 2023. Studies were assessed using a modified Newcastle-Ottawa Scale. Nine studies met inclusion criteria, covering Kazakhstan, Kyrgyzstan, Uzbekistan, Tajikistan, Turkmenistan, Mongolia, Georgia, Armenia, and Azerbaijan. TB incidence ranged from 67 per 100,000 in Kazakhstan to 190 per 100,000 in Kyrgyzstan, with a prevalence of 68.5% in Mongolia. TB affected men more frequently (65.3%), with key risk factors including HIV (30.5%), comorbidities, and undernutrition. Drug-resistant TB imposed a significant economic burden, with treatment costs ranging from $106 to $3,125. Strengthening surveillance, improving data collection, and conducting longitudinal studies are essential for designing effective TB control strategies in these regions.

22 June 2026 in Scientific Reports
Verified
Journal Article
Open access
NKNailya Kozhekenova
Nailya Kozhekenova
NGNatalya Glushkova
Natalya Glushkova
MIMalika Idayat
Malika Idayat
Zhansaya NurgaliyevaZhansaya Nurgaliyeva
Zhansaya Nurgaliyeva
AOAinash Oshibayeva
Ainash Oshibayeva
Milena Santric MilicevicMilena Santric Milicevic
Milena Santric Milicevic
The COVID-19 pandemic prompted extraordinary response measures in Central Asia ( Kazakhstan, Kyrgyzstan, and Mongolia), but mortality outcomes varied. This retrospective population-based ecological study assessed age-standardized COVID-19 mortality rates (ASMRs per 100,000) from January 2020 to December 2021. Monthly COVID-19 deaths and population data by age and sex were obtained from official statistical and health sources. ASMRs were calculated using direct age standardization; monthly trends were examined by country, sex, and age group using joinpoint regression and interpreted in relation to governmental mitigation measures and circulating SARS-CoV-2 variants. Rates were higher in men than in women: in Kazakhstan, 24.8 vs. 12.8 in 2020 and 87.3 vs. 67.6 in 2021, in Kyrgyzstan, 46.6 vs. 25.2 and 40.8 vs. 29.7, respectively; and in Mongolia, 91.5 vs. 73.1 in 2021, with no deaths reported in 2020. In 2021, the gap between men and women narrowed as female ASMR increased fivefold. COVID-19 mortality was observed among infants in Kazakhstan and children ages 0–4 in Mongolia (2021). Rates rose sharply from age 60, especially among men and showed distinct country-specific timing: an early peak in Kyrgyzstan, delayed acceleration in Kazakhstan, and a late rise in Mongolia. These results underscore the need for timely, coordinated, age- and sex-sensitive response measures and targeted protection of vulnerable groups.

15 July 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
OAOyunzul Amartsengel
Oyunzul Amartsengel
MIMalika Idayat
Malika Idayat
ARAlexander Rommel
Alexander Rommel
NGNatalya Glushkova
Natalya Glushkova
KDKairat Davletov
Kairat Davletov
ELElena von der Lippe
Elena von der Lippe
Correction: Trends and disparities in tuberculosis burden in Kazakhstan and Mongolia (2017–2021): a comparative analysis using GBD metricsName of all authors as they appear in the published original article (INSERT ONLY IF correcting author names or adding authors. Insert the correct version of the author list)Affiliations of all authors as they appear in the published original version of the article (INSERT ONLY IF correcting affiliation(s) or adding affiliation(s). Insert the correct version of the affiliation(s))* Correspondence: Malika Idayat: midayatova@gmail.com, Lkhagvasuren Khorolsuren: khorolsuren.l@mnums.edu.mnKeywords: same as original articleCorrection on: full citation of the original version of the article. Incorrect affiliationIn the published article, there was an error in affiliation(s) [6]. Instead of “[Lkhagvasuren Khorolsuren6 *]”, it should be “[Lkhagvasuren Khorolsuren1 *]”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

15 December 2025 in Yassawi Journal of Health Sciences
Verified
Journal Article
Closed access
BTB Toymetov
B Toymetov
ZZZh Zhagiparova
Zh Zhagiparova
MIMalika Idayat
Malika Idayat
This study examines incentive payment schemes in primary care and their impact on healthcare effectiveness and equity. We analyze four principal remuneration models: Fee-for-Service, Capitation Financing, Pay-for-Performance (P4P), and hybrid approaches. Kazakhstan introduced capitation financing with P4P elements in 2009. Our analysis identifies three fundamental paradoxes in this system. First, weak risk-adjustment mechanisms chronically underfund facilities serving vulnerable populations. Second, payment delays undermine financing predictability and create financial instability. Third, incentives for selective patient enrollment contradict universal health coverage goals. The P4P component shows additional weaknesses: questionable quality indicators, inadequate outcome attribution, and poor integration across care levels. Based on international experience (Kyrgyzstan, Uzbekistan, United States), we propose four optimization strategies: strengthening risk-adjustment models; refining P4P mechanisms with emphasis on equity and provider support; eliminating payment delays; and developing comprehensive motivation frameworks that combine adequate base salaries and fair capitation rates with non-financial incentives such as professional development and improved working conditions. Our findings show that financial mechanisms without broader systemic support generate counterproductive incentives. These results inform remuneration policy development, primary care quality improvement, and healthcare expenditure optimization.